Despite the major impact of CKD and, specifically, of DKD on mortality and morbidity, recently, the therapeutic options in the management of patients with this condition have remained limited until recently when sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as new disease-modifying drugs [26]. This evidence concerns the gene SLC5A2 and chronic kidney disease.